PASSIvation of Vulnerable Plaque With AZD5718 in AcuTe Coronary syndromE
Status:
Not yet recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
This is a multi-center study conducted at 13 sites in 3 countries (Singapore, New Zealand,
and the United Kingdom). Approximately 360 patients with an acute myocardial infarction (AMI)
will be randomized in a ratio of 1:1 ratio to receive AZD5718 125 mg or placebo for 12
months.